Palatin/Mallinckrodt LeuTech Is Now NeutroSpec; Second Quarter Approval Predicted
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requested trade name change to avoid confusion with a currently marketed drug, Palatin says. NeutroSpec is pending at FDA for diagnosis of equivocal appendicitis; Palatin completed all BLA amendments in first quarter of 2004.